Karl Härfstrand
Gründer bei Härfstrand Consulting AG
Vermögen: - $ am 31.05.2024
Ursprung des Netzwerks ersten Grades von Karl Härfstrand
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Pharmacia & Upjohn, Inc.
35
| Extinct | Pharmaceuticals: Major | 35 |
| Public Company | Biotechnology | 21 | |
Pharmacia AB
19
| Extinct | Pharmaceuticals: Major | 19 |
| Subsidiary | Pharmaceuticals: Major | 19 | |
Karolinska Institutet
19
| College/University | Other Consumer Services | 19 |
17
| Public Company | Pharmaceuticals: Generic | 17 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.
16
| Subsidiary | Pharmaceuticals: Major | 16 |
Pharmacia, Inc.
11
| Extinct | 11 | |
| Public Company | Financial Conglomerates | 10 | |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.
9
| Subsidiary | Pharmaceuticals: Major | 9 |
| Public Company | Packaged Software | 9 | |
to-BBB technologies BV
 to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands.
2
| Extinct | Pharmaceuticals: Major | 2 |
| Subsidiary | Pharmaceuticals: Major | 2 | |
| Subsidiary | Chemicals: Agricultural | 2 | |
Humabs BioMed SA
 Humabs BioMed SA Miscellaneous Commercial ServicesCommercial Services Humabs BioMed SA is an antibody therapeutics biotechnology company. It develops human monoclonal antibody platforms for treatment of infectious and inflammatory diseases. The company was founded by Prof. Antonio Lanzavecchia on October 24, 2011 and is headquartered in Bellinzona, Switzerland.
1
| Subsidiary | Miscellaneous Commercial Services | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Karl Härfstrand
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
| ENZON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO Director/Board Member | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
| HYPERION THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| APELLIS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Provell Pharmaceuticals LLC
 Provell Pharmaceuticals LLC Medical DistributorsDistribution Services Provell Pharmaceuticals LLC is a healthcare company, which engages in marketing and distribution of pharmaceutical products. It offers products of Merck KGaA including Euthyrox. The company was founded by Jim Small and Kurt Kalm in 2005 and is headquartered in Honey Brook, PA. | Medical Distributors | Director/Board Member Director/Board Member | |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
| HOIST FINANCE AB | Miscellaneous Commercial Services | Comptroller/Controller/Auditor Director/Board Member | |
| University of Cambridge | College/University | Graduate Degree Graduate Degree | |
| OREXO AB | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| New York University | College/University | Masters Business Admin Undergraduate Degree Doctorate Degree | |
| University of Michigan | College/University | Undergraduate Degree Masters Business Admin | |
| Stockholm School of Economics | College/University | Undergraduate Degree Masters Business Admin | |
| University of Uppsala | College/University | Undergraduate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree | |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Private Equity Investor Chairman Chief Executive Officer Chief Executive Officer Director of Finance/CFO | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
The Column Group LLC
 The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Investment Managers | Private Equity Investor Private Equity Investor | |
KAHR Medical Ltd.
 KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Astra Arcus AB | Corporate Officer/Principal President | ||
| Pharmacia Ophthalmics AB | Chairman Corporate Officer/Principal Corporate Officer/Principal | ||
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal | |
| BIOARCTIC AB | Pharmaceuticals: Major | Founder Director/Board Member | |
| KCIF Fund Management AB | Director/Board Member Director/Board Member | ||
SwedenBIO Service AB
 SwedenBIO Service AB Miscellaneous Commercial ServicesCommercial Services SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Corporate Officer/Principal Chief Executive Officer | |
Cobra Biologics Ltd.
 Cobra Biologics Ltd. Pharmaceuticals: MajorHealth Technology Cobra Biologics Ltd. engages in development of DNA-based technologies, services and products. It is a international contract development and manufacturing organization (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The company was founded in 1992 and is headquartered in Keele, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chairman President General Counsel | |
Karolinska University Hospital
 Karolinska University Hospital Hospital/Nursing ManagementHealth Services Karolinska University Hospital is a premier health facility and one of Europe's largest teaching hospitals located in Stockholm, Sweden. The Swedish company provides healthcare services for a wide range of disorders, from major public health diseases to rare medical conditions. As a designated provider of highly specialized medical services, they have a primary responsibility for the clinical components of research and education. Together with the world-respected Karolinska Institutet, they lead in medical breakthroughs. The company educates and train tomorrow's medical specialists and healthcare professionals as a major teaching hospital. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
| Aprea Personal AB | Director/Board Member Chairman | ||
Cobra Biologics Holding AB
 Cobra Biologics Holding AB Pharmaceuticals: MajorHealth Technology Cobra Biologics Holding AB manufactures biologics and pharmaceuticals for pre-clinical, clinical, and commercial products. Its services include gene therapies and vaccines, products for testing, process development and scale up of vaccine products, production of sterile drug products, and process development and production, automation, and traceability of programs. The company was founded in 2011 and is headquartered in S?dert?lje, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
| FOLLICUM AB (PUBL) | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer | |
Cormorant Pharmaceuticals AB
 Cormorant Pharmaceuticals AB BiotechnologyHealth Technology Cormorant Pharmaceuticals AB provides biopharmaceutical products.The company was founded by Maarten de Chateau and Urban Paulsson in 2010 and is headquartered in Solna, Sweden. | Biotechnology | Corporate Officer/Principal Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Undergraduate Degree Masters Business Admin | |
Empros Pharma AB
 Empros Pharma AB Pharmaceuticals: MajorHealth Technology Empros Pharma AB is a pharmaceutical company based in Sweden that focuses on developing drugs to combat obesity. The CEO is Arvid Söderhäll, and the company is located in Solna, Sweden. The Swedish company has developed a weight-loss combination product containing orlistat and acarbose, which has been tested in a randomized, placebo-controlled trial. Empros Pharma's main drug, EMP16, is designed to delay food digestion and absorption processes in the small intestine using a proprietary advanced drug delivery technology. The company was founded in 2013 by senior researchers and entrepreneurs at Uppsala University, along with external investor Flerie Invest. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Flerie Invest AB
 Flerie Invest AB Investment ManagersFinance Flerie Invest AB (Flerie Invest) is a venture capital subsidiary of Flerie Creations Ltd. founded in 2011. The firm is headquartered in Stockholm, Sweden. | Investment Managers | Consultant / Advisor Chairman | |
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IRLAB THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Prokarium Holdings Ltd.
 Prokarium Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Prokarium Holdings Ltd. provides management services. The private company is based in London, UK. The British company was founded in 2014. Kristen Albright has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Buzzard Pharmaceuticals AB
 Buzzard Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Buzzard Pharmaceuticals AB develops oncology drugs. The company is based in Stockholm, Sweden. The Swedish company was founded by Urban Paulsson. The CEO is Maarten de Château. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Aktis Oncology, Inc.
 Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Medical/Nursing Services | Director/Board Member Director/Board Member |
Statistik
International
| Schweden | 25 |
| Vereinigte Staaten | 19 |
| Vereinigtes Königreich | 5 |
| Irland | 2 |
| Deutschland | 2 |
Sektoral
| Health Technology | 28 |
| Consumer Services | 8 |
| Commercial Services | 6 |
| Finance | 5 |
| Health Services | 3 |
Operativ
| Director/Board Member | 516 |
| Corporate Officer/Principal | 244 |
| Chairman | 159 |
| Independent Dir/Board Member | 117 |
| Chief Executive Officer | 103 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Gunnar Magnus Modee Persson | 51 |
| Ulf Rosén | 45 |
| Göran Albert Ando | 44 |
| Thomas Bengt Eldered | 41 |
| Johan Rutger Christenson | 35 |
| Carl-Johan Spak | 35 |
| Bo Jesper Hansen | 34 |
| Helen Kim | 34 |
| Gunilla Öhman | 29 |
| Fred Hassan | 29 |
| James Sapirstein | 26 |
| Laura González Molero | 25 |
| Daniel Welch | 24 |
| Peter Arend William Burema | 23 |
| Craig Tooman | 22 |
- Börse
- Insiders
- Karl Härfstrand
- Unternehmensverbindungen